2026 Q3 Portfolio Activity
In 2026 Q3, Octagon Capital Advisors LP maintained a portfolio of 29 distinct positions. The most significant new addition was OBSIDIAN THERAPEUTICS INC, now representing 4.42% of the total fund value. They heavily accumulated shares in ARRIVENT BIOPHARMA INC, increasing the position by 8.6%. Conversely, Octagon Capital Advisors LP completely exited their position in ALUMIS INC.
Position History
hover any row below to update
Loading…
Total Positions
29
Quarter
2026 Q3
Top Holding
DNTH (19.8%)
Top 10 Concentration
82.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-29 of 29
Octagon Capital Advisors LP Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 19.79% | 16.14% |
#1
Prev: #1
|
6.5 |
—
|
-155,000 | -8.4% |
P
S
|
1,686,667 | $148,511,029 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 13.10% | 11.89% |
#2
1
Prev: #3
|
6.5 |
—
|
no change | no change |
P
S
|
993,000 | $98,326,860 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 12.73% | 12.47% |
#3
1
Prev: #2
|
5.5 |
—
|
-439,000 | -14.9% |
P
S
|
2,511,000 | $95,568,660 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 10.02% | 8.17% |
#4
Prev: #4
|
5.5 |
—
|
no change | no change |
P
S
|
2,350,000 | $75,247,000 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AVBP
ARRIVENT BIOPHA...
|
Healthcare | 8.64% | 6.15% |
#5
1
Prev: #6
|
6.0 |
—
|
170,333 | 8.6% |
P
S
|
2,141,387 | $64,841,198 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 6.29% | 5.93% |
#6
1
Prev: #7
|
3.5 |
—
|
no change | no change |
P
S
|
9,693,244 | $47,206,098 | 2020 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
OBX
OBSIDIAN THERAP...
|
Healthcare | 4.42% | — |
#7
Prev: #—
|
5.3 |
—
|
2,414,610 | — |
NEW
|
2,414,610 | $33,152,595 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 3.05% | 3.20% |
#8
2
Prev: #10
|
1.2 |
—
|
-105,000 | -33.9% |
P
S
|
205,000 | $22,916,950 | 2021 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 2.35% | 1.78% |
#9
7
Prev: #16
|
1.9 |
—
|
no change | no change |
P
S
|
270,000 | $17,674,200 | 2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 2.09% | — |
#10
Prev: #—
|
4.3 |
—
|
630,000 | — |
NEW
|
630,000 | $15,718,500 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 2.08% | 2.66% |
#11
1
Prev: #12
|
1.3 |
—
|
-70,000 | -14.3% |
P
S
|
420,000 | $15,619,800 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ANL
ADLAI NORTYE GR...
|
Healthcare | 1.99% | 0.97% |
#12
7
Prev: #19
|
1.8 |
—
|
no change | no change |
P
S
|
934,716 | $14,955,456 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 1.93% | 3.57% |
#13
4
Prev: #9
|
0.8 |
—
|
-169,450 | -50.0% |
P
S
|
169,450 | $14,484,586 | 2022 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AKTS
AKTIS ONCOLOGY ...
|
Healthcare | 1.85% | 2.78% |
#14
3
Prev: #11
|
0.7 |
—
|
-247,847 | -25.8% |
P
S
|
713,000 | $13,882,110 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PALI
PALISADE BIO IN...
|
Healthcare | 1.85% | 1.93% |
#15
1
Prev: #14
|
1.7 |
—
|
no change | no change |
P
S
|
10,276,317 | $13,873,028 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
CALL
ERASCA INC
|
|
CALL Option | 1.41% | 2.07% |
#16
3
Prev: #13
|
0.6 |
—
|
-535,000 | -42.6% |
P
S
|
720,000 | $10,555,200 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
BIOA
BIOAGE LABS INC
|
Healthcare | 1.23% | 3.85% |
#17
9
Prev: #8
|
0.5 |
—
|
-448,000 | -25.6% |
P
S
|
1,300,000 | $9,217,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 1.05% | 1.42% |
#18
Prev: #18
|
0.4 |
—
|
-207,721 | -45.5% |
P
S
|
249,000 | $7,898,280 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GYRE
GYRE THERAPEUTI...
|
Healthcare | 0.93% | 0.57% |
#19
4
Prev: #23
|
1.4 |
—
|
no change | no change |
P
S
|
954,416 | $6,995,869 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DBVT
DBV TECHNOLOGIE...
|
Healthcare | 0.90% | 0.85% |
#20
1
Prev: #21
|
1.4 |
—
|
no change | no change |
P
S
|
574,200 | $6,752,592 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 0.61% | 1.83% |
#21
6
Prev: #15
|
0.2 |
—
|
-1,475,100 | -71.1% |
P
S
|
599,900 | $4,601,233 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 0.60% | 0.53% |
#22
2
Prev: #24
|
1.2 |
—
|
no change | no change |
P
S
|
315,000 | $4,510,800 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SNSE
FAETH THERAPEUT...
|
Healthcare | 0.40% | 0.81% |
#23
1
Prev: #22
|
0.2 |
—
|
-261,010 | -72.3% |
P
S
|
100,000 | $2,974,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DTIL
PRECISION BIOSC...
|
Healthcare | 0.36% | 0.95% |
#24
4
Prev: #20
|
0.1 |
—
|
-920,000 | -68.1% |
P
S
|
430,000 | $2,691,800 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
UNCY
UNICYCIVE THERA...
|
Healthcare | 0.17% | 0.42% |
#25
Prev: #25
|
0.1 |
—
|
-725,000 | -72.5% |
P
S
|
275,000 | $1,291,125 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GOSS
GOSSAMER BIO IN...
|
Healthcare | 0.15% | 0.11% |
#26
1
Prev: #27
|
0.1 |
—
|
-7,653,125 | -98.8% |
P
S
|
96,875 | $1,147,969 | 2020 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CNTX
CONTEXT THERAPE...
|
Healthcare | 0.00% | 0.15% |
Sold All 😨
(Was: #26) |
0.0 |
—
|
-3,050,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SMMT
SUMMIT THERAPEU...
|
Healthcare | 0.00% | 1.64% |
Sold All 😨
(Was: #17) |
0.0 |
—
|
-1,250,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ALMS
ALUMIS INC
|
Healthcare | 0.00% | 7.16% |
Sold All 😨
(Was: #5) |
0.0 |
—
|
-2,830,700 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-29 of 29 holdings